Melatonin treatment for circadian rhythm sleep disorders

Psychiatry Clin Neurosci. 1998 Apr;52(2):259-60. doi: 10.1111/j.1440-1819.1998.tb01063.x.

Abstract

We administered 1-3 mg melatonin to 11 patients (eight men, three women, aged 16-46 years) with circadian rhythm sleep disorders; nine with delayed sleep phase syndrome and two with non-24-hour sleep-wake syndrome. Sleep logs were recorded throughout the study periods and actigraph and rectal temperature were monitored during treatment periods. Melatonin was administered 1-2 h before the desirable bedtime for expected phase-shifting, or 0.5-1 h before habitual bedtime for gradual advance expecting an hypnotic effect of the melatonin. Melatonin treatments were successful in 6/11 patients. Timing and dose of melatonin administration, together with its pharmacological properties for circadian rhythm sleep disorders, should be further studied.

MeSH terms

  • Adolescent
  • Adult
  • Circadian Rhythm / drug effects*
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Male
  • Melatonin / therapeutic use*
  • Middle Aged
  • Polysomnography
  • Sleep Wake Disorders / drug therapy*
  • Treatment Outcome

Substances

  • Melatonin